Stock listing

Stuttgart:5LB0 BioVaxys Technology Corp Aktie

German listing (Stuttgart) of BioVaxys Technology Corp · home listing CSE:BIOV

Follow BioVaxys Technology Corp into a list and get an email when it puts out news.

Home listing price · CSE:BIOV

$0.07 CAD 0.00 (0.0%)

Close on Oct 22, 2026 · This listing has no price on 6ix; the price shown is the home listing's, CSE:BIOV

Past year -69.6% · daily closes, Oct 22, 2025 – Oct 22, 2026, adjusted for splits

Day range: $0.07 – $0.07 CADOct 22, 2026
Market cap: $2.85M CADAt the close on Oct 22, 2026 · price × 40.65M shares outstanding
52-week range: $0.03 – $0.29 CADLowest and highest trades, Oct 23, 2025 – Oct 22, 2026
Traded on an average day: $0 CADMedian day 0 shares · 64 days with no trades · last 3 months, Jul 22, 2026 – Oct 22, 2026

Prices by listing

Listing	Last	Change	Volume	Open	High	Low	Previous close	Price from
CSE:BIOV · Home	$0.07 CAD	0.00 (0.0%)	—	$0.07	$0.07	$0.07	$0.07	Close on Oct 22, 2026
OTC:BVAXF	$0.09 USD	+0.007 (+9.1%)	12,000	$0.08	$0.09	$0.08	$0.083	Close on Oct 23, 2026

Daily closes

Last 3 months, Jul 22, 2026 – Oct 22, 2026 · CSE:BIOV · CAD, adjusted for splits

Day	Close	%	Open	High	Low
Thu, Oct 22	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Oct 21	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Oct 20	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Oct 19	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Oct 16	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Oct 15	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Oct 14	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Oct 13	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Oct 9	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Oct 8	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Oct 7	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Oct 6	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Oct 5	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Oct 2	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Oct 1	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Sep 30	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Sep 29	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Sep 28	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Sep 25	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Sep 24	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Sep 23	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Sep 22	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Sep 21	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Sep 18	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Sep 17	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Sep 16	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Sep 15	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Sep 14	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Sep 11	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Sep 10	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Sep 9	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Sep 8	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Sep 4	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Sep 3	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Sep 2	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Sep 1	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Aug 31	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Aug 28	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Aug 27	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Aug 26	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Aug 25	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Aug 24	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Aug 21	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Aug 20	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Aug 19	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Aug 18	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Aug 17	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Aug 14	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Aug 13	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Aug 12	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Aug 11	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Aug 10	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Aug 7	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Aug 6	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Aug 5	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Aug 4	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Jul 31	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Jul 30	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Jul 29	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Jul 28	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Jul 27	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Jul 24	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Jul 23	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Jul 22	$0.07	0.0%	$0.07	$0.07	$0.07

Ticker: Stuttgart:5LB0
Asset type: Stock
Sector: Health care
Industry: Biotechnology
Exchange: Stuttgart
Currency: EUR

What changed lately

Latest news release · Sep 8, 2026
BioVaxys Technology Corp. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Latest news

BioVaxys Technology Corp. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Sep 8, 2026

Closed $0.07 (0.0%) on Sep 8, 2026

BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer

May 1, 2026

Closed $0.06 (0.0%) on May 1, 2026

BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 27, 2026

Closed $0.07 (+40.0%) on Apr 27, 2026

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Mar 17, 2026

Closed $0.09 (0.0%) on Mar 18, 2026

BioVaxys Announces Application for Management Cease Trade Order

Mar 3, 2026

Closed $0.12 (-7.7%) on Mar 4, 2026

BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer

Jan 29, 2026

Closed $0.215 (+2.4%) on Jan 29, 2026

BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)

Jan 20, 2026

Closed $0.22 (-8.3%) on Jan 20, 2026

BioVaxys 1Q2026 R&D and Collaborative Activity

Jan 15, 2026

Closed $0.26 (+15.6%) on Jan 15, 2026

BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer

Jan 8, 2026

Closed $0.25 (+8.7%) on Jan 8, 2026

BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

Dec 17, 2025

Closed $0.24 (+9.1%) on Dec 17, 2025

All BioVaxys Technology Corp news

Decks

Investor Presentation (November 2025)
Investor deck · 18 slides · November 2025
Investor Presentation (December 2021)
Investor deck · 44 slides · December 2021
Investor Presentation (February 2021)
Investor deck · 31 slides · February 2021
Investor Presentation (October 2020)
Investor deck · 33 slides · October 2020

BioVaxys Technology Corp on 6ix

Sector: Health care
Industry: Biotechnology
News releases: 13 in the last 12 months · 38 in all · newest Sep 8, 2026 · oldest 2023
Decks: 4 decks · latest November 2025

Where BioVaxys Technology Corp is listed

Listing	Exchange	Country	Currency
CSE:BIOV · Home listing	CSE	Canada	CAD
OTC:BVAXF	OTC	United States	USD
Cboe Canada:BIOV	Cboe Canada	Canada	CAD
Lang & Schwarz:A41C58	Lang & Schwarz	Germany	EUR
LS Exchange:A41C58	LS Exchange	Germany	EUR
Frankfurt:5LB0	Frankfurt	Germany	EUR
gettex:5LB0	gettex	Germany	EUR
Munich:5LB0	Munich	Germany	EUR
Stuttgart:5LB0 · This page	Stuttgart	Germany	EUR

Stuttgart:5LB0 BioVaxys Technology Corp Aktie

Prices by listing

Daily closes

What changed lately

BioVaxys Technology Corp. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Latest news

BioVaxys Technology Corp. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer

BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

BioVaxys Announces Application for Management Cease Trade Order

BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer

BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)

BioVaxys 1Q2026 R&D and Collaborative Activity

BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer

BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

Decks

Investor Presentation (November 2025)

Investor Presentation (December 2021)

Investor Presentation (February 2021)

Investor Presentation (October 2020)

BioVaxys Technology Corp on 6ix

Where BioVaxys Technology Corp is listed